StemSynergy Therapeutics Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Investors
-
5
StemSynergy Therapeutics General Information
Description
Operator of a medical biotechnology company intended to develop therapeutic drugs for cancer treatments. The company specializes in the research and discovery of medications that target biomolecules and cellular processes by targeting the cancer stem/initiating cell (CSC) populations, helping the healthcare industry eliminate tumor growth.
Contact Information
Website
www.stemsynergy.comCorporate Office
- 1951 NorthWest 7th Avenue
- Suite 300
- Miami, FL 33136
- United States
Corporate Office
- 1951 NorthWest 7th Avenue
- Suite 300
- Miami, FL 33136
- United States
StemSynergy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | Completed | Pre-Clinical Trials | ||||
| 12. Grant | 05-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 11. Grant | 01-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 10. Grant | 15-Mar-2018 | Completed | Pre-Clinical Trials | |||
| 9. Grant | 01-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 8. Accelerator/Incubator | 01-Jan-2017 | Completed | Pre-Clinical Trials | |||
| 7. Grant | 01-Jan-2017 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 16-Sep-2016 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 01-Jan-2016 | $675K | Completed | Pre-Clinical Trials | ||
| 4. Grant | 01-Jan-2014 | $1.5M | Completed | Pre-Clinical Trials |
StemSynergy Therapeutics Patents
StemSynergy Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025214920-A1 | Compositions and methods for treating cancer and reducing wnt mediated effects | Pending | 02-Feb-2024 | ||
| US-20250257061-A1 | Compositions and methods for treating cancer and reducing wnt mediated effects | Pending | 02-Feb-2024 | ||
| WO-2025166286-A1 | Compositions and methods for treating cancer and reducing wnt mediated effects | Pending | 02-Feb-2024 | ||
| AU-2021275994-A1 | Notch inhibitors and uses thereof | Inactive | 21-May-2020 | ||
| AU-2021276673-A1 | Notch inhibitors and uses thereof | Inactive | 21-May-2020 | C07D403/12 |
StemSynergy Therapeutics Signals
StemSynergy Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| QB3 | Accelerator/Incubator | |||
| National Cancer Institute | Government | |||
| U.S. Department of Health and Human Services | Government | |||
| UM Ventures | Venture Capital | Minority |
StemSynergy Therapeutics FAQs
-
When was StemSynergy Therapeutics founded?
StemSynergy Therapeutics was founded in 2007.
-
Where is StemSynergy Therapeutics headquartered?
StemSynergy Therapeutics is headquartered in Miami, FL.
-
What is the size of StemSynergy Therapeutics?
StemSynergy Therapeutics has 6 total employees.
-
What industry is StemSynergy Therapeutics in?
StemSynergy Therapeutics’s primary industry is Drug Discovery.
-
Is StemSynergy Therapeutics a private or public company?
StemSynergy Therapeutics is a Private company.
-
What is StemSynergy Therapeutics’s current revenue?
The current revenue for StemSynergy Therapeutics is .
-
Who are StemSynergy Therapeutics’s investors?
National Institutes of Health, QB3, National Cancer Institute, U.S. Department of Health and Human Services, and UM Ventures have invested in StemSynergy Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process